Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Seagen targets Daiichi in cancer drug suit

22 October 2020 US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.

Big Pharma

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

14 November 2019 Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.

Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

2 April 2019 Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

More features

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Philips wins unprecedented trade secret sanctions against Chinese defendants

Womble Bond Dickinson partners jump to rival firm

EPO ruling clarifies appeal rights, blocking third-party intervention

Biotech sues AstraZeneca and Cellectis over mRNA patents

Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

More on this story

Editor's picks

Editor's picks

More features